thiazoles has been researched along with bosutinib in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (27.27) | 29.6817 |
| 2010's | 32 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, J; Quintás-Cardama, A | 2 |
| Ahmed, S; Andreoni, F; Boschelli, F; Cleris, L; Coluccia, AM; Donella-Deana, A; Formelli, F; Gambacorti-Passerini, C; Magistroni, V; Marchesi, E; Piazza, R; Puttini, M; Redaelli, S; Scapozza, L | 1 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S | 1 |
| Kimura, S | 3 |
| Augustin, M; Baumgartner, C; Bennett, KL; Colinge, J; Hantschel, O; Müller, A; Remsing Rix, LL; Rix, U; Stranzl, T; Superti-Furga, G; Till, JH; Valent, P | 1 |
| Chuah, C; Melo, JV | 1 |
| Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R | 1 |
| Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
| Asenova, S; Ayuk, F; Bacher, U; Brummendorf, TH; Klyuchnikov, E; Kröger, N; Ocheni, S; Osanmaz, O; Schafhausen, P; Zabelina, T; Zander, AR | 1 |
| Apáti, A; Hegedus, C; Katona, M; Kéri, G; Magócsi, M; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Szakács, G; Takáts, Z; Váradi, A | 1 |
| Duesberg, P; Fabarius, A; Giehl, M; Haferlach, C; Hochhaus, A; Hofheinz, R; Hofmann, WK; Leitner, A; Seifarth, W | 1 |
| Bennett, KL; Breitwieser, F; Colinge, J; Hartler, J; Remsing Rix, L; Rix, U; Superti-Furga, G; Thallinger, GG; Trajanoski, Z; Ubaida Mohien, C; Winter, GE | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 2 |
| Dempke, W; Zippel, R | 1 |
| Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Shah, R; Wang, L | 1 |
| Okimoto, RA; Van Etten, RA | 1 |
| Baccarani, M; Cortes, JE; Jabbour, E; Kantarjian, HM; Saglio, G | 1 |
| Eadens, M; Messersmith, W; Puls, LN | 1 |
| Bennett, KL; Cerny-Reiterer, S; Gleixner, KV; Gotlib, J; Hadzijusufovic, E; Hörmann, G; Horny, HP; Mayerhofer, M; Meyer, RA; Mitterbauer-Hohendanner, G; Pickl, WF; Reiter, A; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Demarquet, M; Labussière-Wallet, H; Nicolas-Virelizier, E; Nicolini, FE | 1 |
| Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M | 1 |
| Apperley, JF; Bua, M; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Marin, D; Milojkovic, D; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Baccarani, M; Besson, N; Brümmendorf, TH; Cortes, JE; Countouriotis, A; Gambacorti-Passerini, C; Kantarjian, HM; Kelly, V; Khoury, HJ; Kim, DW; Leip, E; Zaritskey, A | 1 |
| Pfirrmann, M; Saussele, S | 1 |
| Boxer, SG; Levinson, NM | 1 |
| Kantarjian, H; Liu-Dumlao, T; O'Brien, S; Ravandi, F; Thomas, DA | 1 |
| Bowles, DW; Green, K; Thienelt, CD | 1 |
| Marin, D | 1 |
| Irvine, E; Williams, C | 1 |
| Blakely, KM; Fathers, KE; Hansford, LM; Kaplan, DR; Marra, M; Moffat, J; Moran, MF; Morozova, O; Smith, KM; Taylor, P; Vojvodic, M | 1 |
| Altiok, S; Bennett, KL; Chamrád, I; Colinge, J; Gridling, M; Haura, EB; Müller, AC; Parapatics, K; Rix, U; Stukalov, A; Superti-Furga, G | 1 |
| Barth, C; Massard, C; Vignot, S | 1 |
| Boiso Moreno, S; Carlsson, B; Gréen, H; Jönsson, JI; Skoglund, K; Vikingsson, S | 1 |
| Abdissa, TT; Johnson, GL; Scott, JE; Tarpley, M | 1 |
| Choi, HG; Dančík, V; Gagnon, J; Graham, DB; Gray, NS; Hussain, MM; Khor, B; Narayan, K; O'Connell, DJ; Perez, JR; Reinecker, HC; Russell, CN; Schreiber, SL; Shamji, AF; Song, JH; Sundberg, TB; Xavier, RJ | 1 |
| Clark, K; Ozanne, J; Prescott, AR | 1 |
| Daniel, KG; Gordian, E; Haura, EB; Li, J; Luddy, K; Mediavilla-Varela, M; Muñoz-Antonia, T; Ohaegbulam, K; Pevzner, Y | 1 |
| Alvarez-Larrán, A; Bautista, G; Bobillo, S; Boqué, C; Cuevas, B; de Las Heras, N; Deben, G; Fernandez, A; García Garay, Mdel C; García-Gutiérrez, V; Giraldo, P; Guinea, JM; Iglesias Pérez, A; Lopez Lorenzo, JL; Maestro, B; Martin Mateos, ML; Martinez-Trillos, A; Mata, I; Ortega, F; Portero, A; Ramirez Sánchez, MJ; Romero, E; Romo Collado, A; Ruiz, C; Sebrango, A; Steegmann, JL; Tallón, J; Valencia, S | 1 |
| Eigendorff, E; Ernst, T; Hochhaus, A; La Rosée, P | 1 |
| Contreras, D; García-Escudero, R; Gutiérrez-Muñoz, C; Lorz, C; Navarro, EM; Paramio, JM; Segrelles, C | 1 |
21 review(s) available for thiazoles and bosutinib
| Article | Year |
|---|---|
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
[Novel anti-CML agents beyond imatinib].
Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
Management of patients with resistant or refractory chronic myelogenous leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Treatment Outcome | 2008 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients].
Topics: Aniline Compounds; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2009 |
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
[Development of ABL tyrosine kinase inhibitors].
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2010 |
[SRC kinases in tumor therapy].
Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2010 |
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Clinical Trials as Topic; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2011 |
Current status of SRC inhibitors in solid tumor malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2011 |
[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia].
Topics: Aniline Compounds; Antineoplastic Agents; Blast Crisis; Dasatinib; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Tyrosine kinase inhibitors in hematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Clinical trials in chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2012 |
An update on dual Src/Abl inhibitors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2012 |
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Neoplasm, Residual; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2012 |
New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2012 |
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Nitriles; Piperazines; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2012 |
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2013 |
[Bone targeted therapies: new agents].
Topics: Aniline Compounds; Benzodioxoles; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Dasatinib; Diphosphonates; Humans; Molecular Targeted Therapy; Nitriles; Parathyroid Hormone-Related Protein; Pyrimidines; Quinazolines; Quinolines; RANK Ligand; Receptors, Chemokine; src-Family Kinases; Thiazoles; Transforming Growth Factor beta1 | 2013 |
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Drug Monitoring; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Nitriles; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Thiazoles | 2015 |
1 trial(s) available for thiazoles and bosutinib
| Article | Year |
|---|---|
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Topics: Adult; Aged; Algorithms; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Pyrimidines; Quinolines; Thiazoles; Treatment Failure; Young Adult | 2012 |
22 other study(ies) available for thiazoles and bosutinib
| Article | Year |
|---|---|
Kinase inhibitors in chronic myelogenous leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Signal Transduction; Thiazoles | 2006 |
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Topics: Aniline Compounds; Animals; Benzamides; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; K562 Cells; Mice; Mice, Nude; Models, Molecular; Mutation; Neoplasms; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; src-Family Kinases; Survival Analysis; Thiazoles; U937 Cells; Xenograft Model Antitumor Assays | 2006 |
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Topics: Aniline Compounds; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dasatinib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid, Accelerated Phase; Leukocytes, Mononuclear; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Nerve Tissue Proteins; Nitriles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Substrate Specificity; Thiazoles | 2009 |
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Topics: Aged; Aniline Compounds; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2009 |
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporins; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Fusion Proteins, bcr-abl; Humans; Indoles; K562 Cells; Neoplasm Proteins; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Substrate Specificity; Thiazoles | 2009 |
Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aniline Compounds; Case-Control Studies; Centrosome; Dasatinib; Female; Fibroblasts; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Mucosa; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2010 |
MASPECTRAS 2: An integration and analysis platform for proteomic data.
Topics: Aniline Compounds; Cell Line, Tumor; Dasatinib; Databases, Protein; Humans; Mass Spectrometry; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Proteomics; Pyrimidines; Quinolines; Software; Thiazoles; User-Computer Interface | 2010 |
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Topics: Aniline Compounds; Animals; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Dasatinib; DNA Damage; Female; Gene Knockdown Techniques; Humans; In Vitro Techniques; MAP Kinase Signaling System; Mice; Mice, Nude; Multiple Myeloma; Mutation; Neovascularization, Pathologic; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Quinolines; RecQ Helicases; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2011 |
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aniline Compounds; Cell Line, Tumor; Dasatinib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mast Cells; Mastocytosis, Systemic; Mutation; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Staurosporine; Thiazoles; Tumor Cells, Cultured | 2011 |
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thiazoles; Time Factors; Transcription, Genetic; Treatment Outcome | 2012 |
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Topics: Aniline Compounds; Benzamides; Binding Sites; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isomerism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Recombinant Proteins; Spectrophotometry, Infrared; Static Electricity; Thiazoles; X-Ray Diffraction | 2012 |
A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
Topics: Aniline Compounds; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dasatinib; Gene Expression Profiling; Humans; Lymphoma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; src-Family Kinases; Thiazoles | 2013 |
A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.
Topics: Aniline Compounds; Animals; Biopsy; Carcinoma, Non-Small-Cell Lung; Chromatography, Affinity; Dasatinib; Humans; K562 Cells; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Annotation; Molecular Targeted Therapy; Neoplasm Transplantation; Nitriles; Protein Interaction Maps; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Quinolines; Thiazoles | 2013 |
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line; Cell Membrane; Dasatinib; Genetic Variation; Genotype; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nitriles; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Transduction, Genetic | 2014 |
Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Triple Negative Breast Neoplasms | 2014 |
Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells.
Topics: Aniline Compounds; Animals; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cytokines; Dasatinib; Dendritic Cells; Drug Evaluation, Preclinical; Humans; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-10; Intestine, Small; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinolines; Signal Transduction; T-Lymphocytes, Regulatory; Thiazoles; Transcription Factors | 2014 |
The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Topics: Aniline Compounds; Animals; Arginase; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cytokines; Dasatinib; Immunity, Innate; Macrophages; Mice; Nitriles; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinolines; Thiazoles; Transcription Factors; Tumor Necrosis Factor Ligand Superfamily Member 14 | 2015 |
Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Humans; Intracellular Space; Lung Neoplasms; Molecular Docking Simulation; Nitriles; Protein Conformation; Protein Serine-Threonine Kinases; Pyrimidines; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad3 Protein; Thiazoles; Transforming Growth Factor beta | 2014 |
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Topics: Adult; Aged; Aniline Compounds; Antineoplastic Agents; Benzamides; Compassionate Use Trials; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Retrospective Studies; Spain; Survival Analysis; Thiazoles | 2015 |
Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Combinations; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Mice; Mice, Nude; Nitriles; Proto-Oncogene Proteins c-abl; Quinolines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |